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limited success for complications of 
pandemic (H1N1) 2009 (5). Its broad-
er use in treating critically ill patients 
has been limited, however, because 
ECMO requires substantial institution-
al and multidisciplinary commitment 
for implementation and is typically 
only available at major medical centers 
offering cardiovascular surgery.
Although we cannot say speciﬁ  -
cally why our patient survived, clearly, 
aggressive and comprehensive empiric 
treatment, physiologic support, and 
close multidisciplinary communication 
were vital to managing the condition of 
this critically ill patient. ECMO may 
have assisted in organ recovery and pa-
tient survival. However, further studies 
should be conducted to critically evalu-
ate ECMO in the armamentarium of 
therapeutic options for severe pandem-
ic (H1N1) 2009 respiratory failure. 
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To the Editor: We report a mild 
to moderate respiratory disease in 
patients seeking treatment for in-
ﬂ   uenza-like illness (ILI) within the 
ﬁ  rst 8 weeks of an outbreak of inﬂ  u-
enza A pandemic (H1N1) 2009 virus 
(pandemic [H1N1] 2009) infection 
in the Province of Buenos Aires. The 
ﬁ  rst cases of pandemic (H1N1) 2009 
in Argentina were reported in early 
May 2009 in travelers returning from 
Mexico and the United States. In mid-
June, a sharp increase was reported 
in the number of patients with acute 
respiratory symptoms who were seek-
ing treatment in emergency rooms. By 
July 9th, the Argentinean Ministry of 
Health had conﬁ  rmed 2,677 cases and 
82 deaths; most of those infected were 
residents of Buenos Aires and the sur-
rounding area (1). When the World 
Health Organization raised the pan-
demic level to 6, >80% of circulating 
inﬂ  uenza A virus in Argentina was sub-
type H1N1 (2). At the Hospital Central 
de San Isidro, a tertiary hospital of 160 
beds in the Province of Buenos Aires, 
initial clinical evaluation of patients 
with ILI symptoms included physical 
examination and, eventually, chest ra-
diograph and pulse oximetry. Because 
diagnostic resources were limited, pa-
tients with ILI were eligible to receive 
oseltamivir with no prior sampling for 
respiratory pathogens. A standardized 
form was used for prescription and 
data collection, including demographic 
data, history of inﬂ  uenza vaccination, 
date symptoms began, and coexisting 
illnesses. From June 16 to July 5, a 
total of 2,135 patients with ILI were 
evaluated. The age of patients ranged 
from 14 to 82 years of age (median, 
35 years); 854 patients (40 %) were 
male. Because of lower respiratory 
disease, a total of 166 (8%) of 2,135 
patients were admitted to the internal 
medicine ward (n = 139) or to the in-
tensive care unit (n = 27). At admis-
sion, patients had >1 of the following: 
diffuse pulmonary inﬁ  ltrates, room air 
oxygen saturation <95%, crackles on 
auscultation. Other clinical manifes-
tations were not statistically different 
from those already reported in patients 
with pandemic (H1N1) 2009 in the 
United States, including cough, fever, 
and sore throat (3). The most common 
radiology pattern was basal, and bi-
lateral interstitial inﬁ  ltrates were con-
sistent with primary viral pneumonia. 
Notably, some patients had clinical 
radiologic dissociation characterized 
by cough and pulmonary inﬁ  ltrates in 
the absence of fever. Median time of 
hospitalization was 36 hours (range 
1–25 days). No signiﬁ  cant differences 
were observed between the groups 
of patients that were admitted versus 
outpatients in terms of age, sex, num-
ber of days from initiation of fever 
to  ﬁ  rst hospital visit, and history of 
inﬂ  uenza vaccination. A total of 163 
(98%) of 166 patients admitted to the 
hospital during the observation pe-
riod were discharged with no further 
complications.
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Patients admitted to the hospital 
with pulmonary inﬁ  ltrates were em-
pirically treated with high dose oselta-
mivir (150 mg 2×/d) for 5 days, other 
antimicrobial drugs, and, eventually, 
steroids. In 2 patients, the respira-
tory disease progressed initially but 
they eventually recovered; 2 patients 
(1.2% of admissions to hospital) with 
acute respiratory failure died. Despite 
improvement in clinical symptoms 
at discharge, chest radiographs per-
formed on a limited number of pa-
tients showed no substantial changes 
at 72–96 h after admission.
Clinical manifestations of pan-
demic (H1N1) 2009 have not yet been 
fully characterized. We observed a 
mild to moderate lower respiratory 
disease in ≈8% of consecutive patients 
with ILI during the current pandemic 
in Argentina. A more severe respira-
tory disease was observed in Mexico 
during the current pandemic (4) In 
contrast, early reports indicated that 
pandemic (H1N1) 2009 disease might 
be similar in severity to seasonal inﬂ  u-
enza (3). A lack of microbiologic con-
ﬁ   rmation may bias our observation. 
Because pulmonary inﬁ  ltrates are un-
common in previously healthy persons 
with ILI, a simultaneous circulation of 
other respiratory pathogens may ex-
plain our observation. Furthermore, 
early empirical use of antimicrobial 
drugs could overshadow clinical fea-
tures of bacterial pneumonia.
We observed an unexpectedly 
high rate of lower respiratory disease 
in adults with ILI during an outbreak 
of pandemic (H1N1) 2009 in Argenti-
na. This ﬁ  nding suggests that a unique 
pattern of virulence, pulmonary tro-
pism, or both may characterize the 
current inﬂ  uenza A (H1N1) infection, 
although we could not rule out co-in-
fection with other viral or bacterial re-
spiratory pathogens. Considering the 
evolving nature of inﬂ  uenza viruses, 
the wide clinical spectrum of pan-
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Susceptibility of 
Poultry to Pandemic 
(H1N1) 2009 Virus
To the Editor: During April 
2009, cases of acute respiratory dis-
ease in humans caused by inﬂ  uenza 
A pandemic (H1N1) 2009 virus in 
Mexico were reported (1). By Au-
gust 21, 2009, a total of >182,166 
human cases, including 1,799 deaths, 
had been reported from 177 countries 
(www.who.int/csr/don/2009_08_21/
en/index.html). 
The origin of the new virus ap-
pears to be a reassortant event of a 
virus from swine in North America 
that contained the classic swine, hu-
man, and avian inﬂ  uenza genes and a 
virus of unknown origin that contrib-
uted neuraminidase and matrix genes 
of swine in Europe. On May 2, 2009, 
the ﬁ  rst nonhuman infections were de-
tected in a swine operation in Canada 
(www.who.int/csr/don/2009_06_24/
en/index.html).
Historically, human seasonal in-
ﬂ  uenza A viruses have not been report-
ed to infect poultry, but clinical cases 
of respiratory disease or reduction in 
egg production have been reported for 
domestic turkeys after infection with 
subtypes H1N1, H1N2, and H3N2 
swine inﬂ  uenza viruses and for mul-
tiple poultry species with subtype 
H1N1 avian inﬂ   uenza virus (2–4). 
The presence of avian and swine inﬂ  u-
enza virus genes in pandemic (H1N1) 
2009 virus increases the potential for 
infection in poultry after exposure to 
infected humans or swine.
To determine infectivity potential, 
3-week-old chickens (Gallus domes-
ticus) (n = 11), 2-week-old domestic 
ducks (Anas platyrhynchos) (n = 11), 
73-week-old reproductively active 
turkey hens (Meleagris gallopavo) (n 
= 9), 3-week-old turkey poults (n = 
11), and 5-week-old Japanese quail 
(Coturnix japonica) (n = 11) were 
intranasally inoculated with 106 mean 
chicken embryo infectious doses of 
A/Mexico/4108/2009(H1N1). Five 
uninfected chickens, ducks, turkey 
poults, and quail, and 3 uninfected 
turkey hens were contact exposed to 
intranasally inoculated birds to as-
sess transmission potential. Cloacal 
and oropharyngeal swabs were taken 
on 2, 4, 7, and 10 days postinocula-
tion (DPI) from all birds, and internal 
tissues were taken from 2 birds on 2, 
4 and 7 DPI for virus detection by 
quantitative real-time reverse tran-
scription–PCR (qRRT-PCR) assay 
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